Purification of the CMG complex. (A) Purification schematic. See the supporting information for additional details. (B) Material eluted from the anti-Cdc45 IP after the Mono Q step was separated by SDS/PAGE and visualized by Deep Purple stain. For improved resolution of individual bands, the image is composed of the eluate separated by two different acrylamide gels: 9% (top of gel to IgG) and 12% (IgG to bottom of gel). The complete lane of each gel used for this image is shown in Fig. 6. All subsequent gels in this study are 10% acrylamide and contain all proteins in one complete lane. (C) At the Superdex-200 step shown in A, each fraction was subjected to an anti-Cdc45 IP, and the individual eluates were separated on SDS/PAGE and immunoblotted with antibodies against the indicated proteins. The antibodies have variable staining intensity; the ratio of all CMG proteins to each other in the high-molecular-weight fractions is the same (see B, , and 6).

IPs with antibodies against different CMG complex members. In this figure, the proteins were identified by immunoblot and R_f value. (A) (Left) FLAG-Mcm6 material purified from embryo extracts by anti-FLAG chromatography. (Right) From the material first purified by the anti-FLAG chromatography, an anti-Cdc45 IP and a control (rabbit IgG) IP were performed. The anti-Cdc45 immunoprecipitated material shown here is enriched for Cdc45 ≈70-fold over the purified FLAG-Mcm6 material (i.e., ≈700 μl of the material in Left was used to obtain 10 μl of the material in Right). Both gels were stained with Deep Purple. (B) Peak Cdc45-containing fractions from the Mono Q step were precipitated with anti-Psf2 antibodies and control antibodies (anti-FLAG), and the eluates were stained with Deep Purple.

The CMG complex is a helicase. (A) Schematic of the purification protocol used for the helicase assay. (B) Illustration of helicase substrate (not to scale). (C) (Top) PhosphorImager picture of helicase assays with anti-Cdc45 peptide B-purified material from each Mono Q fraction. (Middle) Quantitation of the percentage of primers displaced from duplex DNA in each helicase reaction. (Bottom) Immunoblot with antibodies against indicated proteins of the anti-Cdc45 peptide B-purified material from each Mono Q fraction. The Cdc45 protein peak in fractions 12–15 is monomeric Cdc45 that has copurified with the CMG complex until this chromatography step. (Left) Deep Purple stain of anti-Cdc45 peptide B-purified material from fraction 20. (D) (Left) Immunoblots of material that has been immunodepleted with anti-Psf2, anti-Mcm5, or control antibodies. (Right) PhosphorImager picture of helicase assays with protein purified by anti-Cdc45 peptide B IPs from material previously depleted with anti-Psf2, anti-Mcm5, or control antibodies. (E) (Left) Helicase assays with material mock-eluted or Cdc45 peptide B-eluted from anti-Cdc45 peptide B IPs from purified FLAG-Mcm6 material. (Center) Helicase assays with and without ATP with CMG complex isolated from purified FLAG-Mcm6 material. (Right) Helicase assays with CMG complex purified as in A and with varying concentrations of ATP.

CMG directionality and processivity. (A) (Left) Cartoon of procedure for preparing substrates for directionality assays. A 48-mer primer was annealed to m13mp18 ssDNA plasmid and then labeled with ³²P at the 5′ end with T4 polynucleotide kinase and [γ-³²P]ATP or at the 3′ end with T7 DNA polymerase and [α-³²P]dGTP. The duplex region was digested with SmaI, creating a linear plasmid with ssDNA in the middle and duplex DNA at both ends (the 5′ labeled primer is 20 bases, and the 3′ labeled primer is 28 bases). The radiolabeled primer can only be approached on ssDNA from one direction, thereby allowing determination of the directionality of helicase movement on DNA. (Right) PhosphorImager picture of CMG complex tested with both directionality substrates. (B) The primer in B was extended by the DNA polymerase of T7 (Sequenase), and the heterogeneous products created substrates for helicase assays. A PhosphorImager picture of DNA substrates after incubation in helicase assays with increasing amounts of CMG or Mcm4,6,7 complexes is shown. For measuring the lengths of the duplex DNA in the substrates, a dsDNA ladder was labeled with ³²P and separated on the gel in either native or boiled form.

Cdc45 and GINS proteins are required for normal S phase progression. (A) (Left) Drosophila Kc tissue culture cells were treated with ≈500 bp of dsRNA directed against Cdc45, Sld5, Psf1, Psf2, Psf3, or nonspecific (NS) RNA. After 8 days of RNAi treatment, cells were harvested; FACS profiles are shown. The x axis is arbitrary fluorescence units, and the y axis is the number of cells (0–128). (Right) Cell cycle distribution of RNAi-treated cells. (B) A model of the CMG complex. Green, Mcm2–7; blue, GINS; yellow, Cdc45.